Diamour®, a newly vitrification device for human blastocysts, provides the same efficient perinatal outcomes as the commonly used Cryotop®

Abstract

ObjectiveThe purpose of this study was to investigate the effectiveness of Diamour®, a newly developed vitrification device, for the ultra-rapid frozen storage of human blastocysts. Materials and methodsSurplus blastocysts obtained using assisted reproductive technology at our clinic during a 2-year period (2018–2019) were assigned for vitrification with the Diamour® device in 2019 or a comparator device in 2018. We retrospectively compared outcomes (clinical pregnancy rate, abortion rate, live birth rate, and perinatal outcomes) between the two vitrification devices. ResultsWe obtained 228 blastocysts from 178 patients, and 118 blastocysts were cryopreserved using the Diamour® vitrification device and the other 110 were cryopreserved using a Cryotop®, the comparator device. We found no significant difference between the Diamour®-vitrified and comparator-vitrified blastocysts in clinical pregnancy rate (32.2% vs. 30.9%; p = 0.83), abortion rate (17.0% vs. 9.1%; p = 0.08), and live birth rate (25.4% vs. 26.4%; p = 0.87). The Diamour®-vitrified blastocysts yielded 30 live births, and the comparator-vitrified blastocysts 29. The two devices yielded no significant difference in birth weight (Diamour®: 3049 ± 337 g, comparator: 3008 ± 340 g; p = 0.65) and congenital abnormalities, with just 1 case (cleft lip) noted with Diamour® vitrification (p = 0.33). The devices also showed no significant differences in the incidence of gestational diabetes mellitus, hypertensive disorders of pregnancy, placenta previa, preterm birth, macrosomia, low birth weight, and delivery method. ConclusionThe Diamour® device achieves outcomes similar to those of the currently widely used Cryotop® device for clinical pregnancy with frozen-thawed human blastocysts.